Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer's disease

Neurobiology of Aging

Volumn 23, Issue 2, 2002, Pages 205-211

  Riemenschneider, M ^a   Schmolke, M ^b   Lautenschlager, N ^a   Vanderstichele, H ^c   Vanmechelen, E ^c   Guder, W G ^b   Kurz, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

^c INNOGENETICS   (Belgium)

Author keywords

Alzheimer's disease; Apolipoprotein E; Apolipoprotein E genotype; Beta amyloid; Cerebrospinal fluid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA42 PROTEIN; APOLIPOPROTEIN E; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; STRATIFICATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; COGNITION; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS;

EID: 0036172648     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00272-X     Document Type: Article

References (56)

1. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype
2. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein ε4 allele
3. V717F transgenic mouse model of Alzheimer's disease
4. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
5. Hydrogen peroxid mediates amyloid β protein toxicity
6. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease
7. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
8. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
9. 'Mini Mental State'. A practical method for grading the cognitive state of patients for the clinician
10. Intraneuronal Aβ42 accumulation in human brain
11. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
12. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls
13. Effects of apolippoprotein E β-very low density lipoproteins and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro
14. Apolipoprotein E isoform-dependent amyloid deposition, and neuritic degeneration in a mouse model of Alzheimer's disease
15. Improved discrimination of Alzheimer's disease patients using beta-amyloid (1-42) and tau levels in CSF
16. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43)
17. Apolipoprotein E type 4 allele, and Alzheimer's disease: Effect on age at onset, and relative risk in different age groups
18. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease, and other forms of dementia is reduced but without any correlation to the apoE4 Isoform
19. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease
20. Apolipoprotein E (apoE) polymorphism, and its influence on ApoE concentrations in the cerbrospinal fluid in Finnish patients with Alzheimer's disease
21. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein
22. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
23. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
24. Cerebrospinal fluid apolipoprotein E level is increased in late onset Alzheimer's disease
25. Glial cytokines in Alzheimer's disease: Review and pathogenic implications
26. Apolipoprotein E immunoreactivity in cerebral amyloid deposits, and neurofibrillary tangles in Alzheimer's disease, and kuru plaque amyloid in Creutzfeld-Jakob disease
27. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
28. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro
29. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
30. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice
31. B-amyloid induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease
32. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease
33. Relationship between apolipoprotein E4 allele and CSF amyloid β-protein in Alzheimer's disease and controls
34. Apolipoprotein E levels (apoE) in brain of Alzheimer's disease patients, and controls
35. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
36. Apolipoprotein E in animal models of CNS injury, and in Alzheimer's disease
37. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline
38. Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop
39. Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non Alzheimer's dementia?
40. CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
41. Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes
42. CSF beta-amyloid, cognition, and apoE genotype in Alzheimer's disease
43. Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease
44. Physiological production of the b-amyloid protein and the mechanism of Alzheimer's disease
45. Apolipoprotein E: An important gene, and protein to follow in laboratory medicine
46. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions
47. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease
48. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer's disease
49. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF
50. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery
51. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro
52. Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease
53. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease
54. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides
55. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning